- Stocks
- Pharma & Healthcare
- Dishman Pharma
Dishman Pharma share price
NSE: DPC02Pharma & HealthcareBiotechnology
Dishman Pharma at a glance
With a market capitalisation of ₹2,676 Cr, it ranks 1022nd by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Biotechnology.
Its return on equity was 11.8% in FY16.
Key numbers
- Market cap
- ₹2,676 CrRank 1022 on NSE
- Price to book
- 1.87×FY16
- ROE
- 11.8%FY16
- ROCE
- 8.4%FY16
- Debt to equity
- 0.58FY16
- Net profit margin
- 12.2%FY15
- Book value / share
- ₹179.26FY16
- Dividend payout
- 5.8%FY16
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | — | — | — | — | — |
Dishman Pharma financials
| Item | FY11 | FY12 | FY13 | FY14 | FY15 | FY16 |
|---|---|---|---|---|---|---|
| Revenue | ₹1,031 Cr | ₹1,124 Cr | ₹1,272 Cr | ₹1,385 Cr | ₹1,575 Cr | ₹1,596 Cr |
| Operating profit | ₹91 Cr | ₹88 Cr | ₹145 Cr | ₹156 Cr | ₹159 Cr | ₹233 Cr |
| Net profit | ₹80 Cr | ₹57 Cr | ₹100 Cr | ₹109 Cr | ₹120 Cr | ₹171 Cr |
| EPS (₹) | ₹10.00 | ₹7.00 | ₹12.00 | ₹14.00 | ₹15.00 | ₹21.00 |
| Cash from operations | ₹203 Cr | ₹154 Cr | ₹137 Cr | ₹345 Cr | ₹286 Cr | ₹279 Cr |
| Total debt | ₹444 Cr | ₹512 Cr | ₹469 Cr | ₹380 Cr | ₹330 Cr | ₹419 Cr |
| Shareholders' equity | ₹878 Cr | ₹930 Cr | ₹1,031 Cr | ₹1,177 Cr | ₹1,238 Cr | ₹1,452 Cr |
Dishman Pharma vs peers
The listed Pharma & Healthcare companies nearest to Dishman Pharma by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| ADVENZYMESAdvanced Enzyme Technologies | ₹265.45 | +1.39% | −13.2% | ₹2,972 Cr | 17.6 | — |
| SHUKRAPHARShukra Pharma | ₹63.62 | −7.18% | — | ₹2,797 Cr | 127.2 | — |
| DPC02Dishman Pharma | — | — | — | ₹2,676 Cr | — | — |
| HIKALHikal | ₹210.01 | −0.52% | −11.8% | ₹2,589 Cr | — | — |
| DRAGARWQDr Agarwals Eye Hospital | ₹5,025.00 | +0.12% | — | ₹2,428 Cr | — | — |
| VENUSREMVenus Remedies | ₹1,796.10 | +5.00% | +293.9% | ₹2,401 Cr | 23.3 | — |
| ALEMBICLTDAlembic | ₹92.33 | +0.21% | −2.9% | ₹2,371 Cr | 7.5 | — |
Ask anything about Dishman Pharma
Pivot answers on the live chart with evidence you can check, and tests strategies against DPC02's own history. Try: “Why has DPC02 moved over the last three months?” · “Backtest a 50-day moving-average crossover on DPC02 over five years” · “Compare DPC02 with ADVENZYMES on margins and valuation”
Frequently asked questions about Dishman Pharma
What is the market cap of Dishman Pharma?
Dishman Pharma's market capitalisation is ₹2,676 Cr (₹2,676 Cr) at the 22 Oct 2026 close, ranking 1022nd among the NSE companies Pivot tracks.
What is the ROE and ROCE of Dishman Pharma?
Return on equity was 11.8% in FY16 and return on capital employed was 8.4% in FY16 (consolidated figures).
Is Dishman Pharma a debt-free company?
No. Dishman Pharma's debt-to-equity ratio was 0.58 in FY16, with total debt of ₹419 Cr.
Who are Dishman Pharma's competitors?
The listed Pharma & Healthcare companies closest to Dishman Pharma by market cap are Advanced Enzyme Technologies, Shukra Pharma, Hikal, Dr Agarwals Eye Hospital, Venus Remedies and Alembic.
Is Dishman Pharma a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Dishman Pharma's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on DPC02 against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with D · all NSE stocks · this page as text